Airborne transmission of BHV1, BRSV, and BVDV among cattle is possible under experimental conditions

To control the diseases caused by bovine herpesvirus 1 (BHV1), bovine respiratory syncytial virus (BRSV), and bovine virus diarrhoea virus (BVDV), it is crucial to know their modes of transmission. The purpose of this study was to determine whether these viruses can be transmitted by air to a substantial extent. Calves were housed in two separate isolation stables in which a unidirectional airflow was maintained through a tube in the wall. In one stable, three of the five calves were experimentally infected with BHV1 and later with BRSV. In the BVDV experiment, two calves persistently infected with BVDV (PI-calves) instead of experimentally infected calves, were used as the source of the virus. In all the calves infections were monitored using virus and antibody detection. Results showed that all the three viruses were transmitted by air. BHV1 spread to sentinel calves in the adjacent stable within three days, and BRSV within nine days, and BVDV spread to sentinel calves probably within one week. Although airborne transmission is possibly not the main route of transmission, these findings will have consequences for disease prevention and regulations in control programmes

Vaccination of cattle against bovine viral diarrhoea

This brief review describes types and quality (efficacy and safety) of bovine viral diarrhoea virus (BVDV) vaccines that are in the market or under development. Both conventional live and killed vaccines are available. The primary aim of vaccination is to prevent congenital infection, but the few vaccines tested are not highly efficacious in this respect, as shown in vaccination-challenge experiments. Vaccination to prevent severe postnatal infections may be indicated when virulent BVDV strains are prevalent. Live BVDV vaccines have given rise to safety problems. A complication for the development of BVDV vaccines is the wide antigenic diversity among wild-type BVDV. There is ample room for improvement of both the efficacy and safety of BVDV vaccines, and it may be expected that better vaccines, among which marker vaccines, will be launched in the future

Reduction of veterinary antimicrobial use in the Netherlands. The Dutch success model

Use of antimicrobials in animals poses a potential risk for public health as it contributes to the selection and spread of antimicrobial resistance. Although knowledge of the negative consequences of extensive antimicrobial use in humans and animals accumulated over the decades, total therapeutic antimicrobial use in farm animals in the Netherlands doubled between 1990 and 2007. A series of facts and events formed a window of opportunity to reduce antimicrobial use in farm animals. The recent discovery of significant reservoirs of antimicrobial-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and extended spectrum beta-lactamase-producing bacteria (ESBL) in farm animals, with potential public health implications, combined with an increasing lack of confidence of the public in intensive livestock industries, and discrepancy between the very low antimicrobial use in humans and high use in animals, resulted in intensive collaboration between the government, veterinary professional organizations and important stakeholders within the livestock sector. A combination of compulsory and voluntary actions with clear reduction goals resulted in a 56% reduction in antimicrobial use in farm animals in the Netherlands between 2007 and 2012 and aims at accomplishing a 70% reduction target in 2015. This article describes and analyses the processes and actions behind this transition from an abundant antimicrobial use in farm animals towards a more prudent application of antimicrobials in farm animals in the Netherlands

A subunit vaccine based on glycoprotein E2 of bovine virus diarrhea virus prevents fetal infection in sheep

The primary aim of a bovine virus diarrhea virus (BVDV) vaccine is to prevent transplacental transmission of virus. E2 genes of three BVDV strains, belonging to antigenic groups IA, IB and II, were expressed in insect cells. Three groups of 12 ewes were immunized twice with one of the E2 proteins. A fourth group served as a control. The ewes were served and the pregnant ewes of each vaccination group were allotted to three different challenge groups. Seven weeks after the second vaccination the ewes were challenged intranasally with one of the three BVDV strains. Three weeks later the fetuses were removed and fetal organs were collected for virus isolation. At the day of challenge all vaccinated ewes had neutralizing antibodies against the homologous BVDV strains. One E2 subunit vaccine prevented fetal infection after homologous challenge

Distribution of bovine virus diarrhoea virus in tissues and white blood cells of cattle during acute infection

This study is performed to gain knowledge about the quantitative distribution of bovine virus diarrhoea virus (BVDV) in tissues and white blood cells (WBC) at different intervals after acute infection. Ten specific pathogen-free calves were intranasally inoculated with 105 50% tissue culture infective dose of the non-cytopathic BVDV strain 4800. Twelve hours after inoculation tonsil biopsies were taken and WBC were collected daily for virus isolation and titration. Each day one calf was killed and virus isolations and titrations were performed from a range of tissues. The results indicate that BVDV first replicates in nasal mucosa and to high titers in the tonsil. The virus then appeared to spread to the regional lymph nodes and then disseminates throughout the body. The virus titers were highest in tonsil, thymus and ileum and were low in the WBC. Also after in vitro infection virus titers in WBC were very low, whereas, they were high in epithelial cells. Although the WBC might not be as important as other cells for replication of BVDV, they may play a role in the spread of the virus throughout the body. Copyright (C) 1998 Elsevier Science B.V

Antigenically different pestivirus strains induce congenital infection in sheep: a model for bovine virus diarrhea virus vaccine efficacy studies

To study the efficacy and safety of bovine virus diarrhea virus (BVDV) vaccines there is need for a valid challenge model. We investigated whether sheep can be used in such a challenge model. We intranasally inoculated six groups (A-F) of seronegative sheep at day 49 of gestation with either of five antigenically different BVDV strains and one border disease virus strain. A seventh group (G) was housed for 10 days with a persistently infected calf and an eighth group (H) served as control. From each group half of the sheep were killed at 2 weeks, and half at 4 weeks after infection. For virus isolation five organs were collected from the sheep and seven from the fetuses. All sheep of groups A and H remained seronegative in the ELISA and in the serum neutralization test. At 2 and 4 weeks after infection virus was isolated from almost all fetal organs in six groups. In group A and in the control group no virus was isolated from the fetal organs. The virus distribution patterns in fetuses from sheep housed with the persistently infected calf or intranasally inoculated with the same strain were similar. We concluded that (i) antigenically different BVDV strains can induce congentital infection in sheep and that (ii) the consequences of a contact infection were similar to those after intranasal infection. In a second experiment we infected two groups of seronegative sheep with one of the strains used in the first experiment, before mating. A control group was left uninfected. The sheep were served and all sheep were challenged with antigenically homologous or heterologous BVDV at day 49 of pregnancy. Three weeks after challenge, sheep were killed and the procedure as in the first experiment was followed. None of the fetuses of the infected sheep were virus positive whereas all fetuses of the control sheep were virus positive. Hence, the immune response after BVDV infection protects fetuses against homologous and heterologous infection during pregnancy. Sheep may therefore be used in vaccination-challenge experiments to evaluate BVDV vaccine efficacy in preventing congenital infection

An experimental multivalent bovine virus diarrhea virus E2 subunit vaccine and two experimental conventionally inactivated vaccines induce partial fetal protection in sheep

The primary aim of a bovine virus diarrhea virus (BVDV) vaccine is to prevent transplacental transmission of virus. We studied the efficacy of two experimental conventionally inactivated vaccines, based on BVDV strain Singer and containing a different antigen amount, against three antigenically different BVDV strains in a vaccination-challenge experiment in sheep. We also studied the efficacy of an experimental multivalent E2 subunit vaccine against four antigenically different BVDV strains. The vaccine contained the glycoproteins E2 of BVDV strains that belong to antigenic groups IA, IB and II. All three vaccines induced neutralizing antibodies against all challenge strains. Only the conventional vaccine that contained the highest antigen amount induced complete protection against homologous challenge. Neither of the conventional vaccines provided complete protection against heterologous challenge. The multivalent subunit vaccine induced partial protection against the homologous challenge strains. However, the immune response did inhibit virus replication in ewes, as shown by the results of the virus titrations.</p

Simultaneous intramammary and intranasal inoculation of lactating cows with bovine herpesvirus 4 induce subclinical mastitis

In this study, we examined whether an experimental bovine herpesvirus 4 (BHV4) infection can induce bovine mastitis, or can enhance bovine mastitis induced by Streptococcus uberis (S. uberis). Four lactating cows were inoculated intramammarily and intranasally with BHV4, and four lactating control cows were mock-inoculated. After 14 days, two of four cows from each group were inoculated intramammarily with S. uberis. No clinical signs were recorded in cows inoculated only with BHV4, and their milk samples showed no abnormal morphology, despite the fact that BHV4 replicated in inoculated quarters. Somatic cell count increased significantly in milk from three of six BHV4-inoculated quarters, compared to the non-inoculated quarters of the same cows (within-cow) and the quarters of mock-inoculated cows (control group) on days 8, 9 and 11 post-inoculation (pi). BHV4 was isolated from nasal swabs between days 2 and 9 pi. Clinical mastitis was observed in all four cows intramammarily inoculated with S. uberis. A preceding BHV4 infection did not exacerbate the clinical mastitis induced by S. uberis. S. uberis infections appeared to trigger BHV4 replication. From one quarter of each of two cows inoculated with BHV4 and S. uberis, BHV4 was isolated, and not from quarters inoculated with BHV4 only. In conclusion, BHV4 did not induce bovine clinical mastitis after simultaneous intranasal and intramammary inoculation. However, the BHV4 infection did induce subclinical mastitis in 50% of the cows and the quarters